Sangamo Therapeutics (NASDAQ:SGMO) Receives Buy Rating from HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $10.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 358.72% from the stock’s current price.

Other research analysts also recently issued reports about the company. Barclays increased their price objective on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday. StockNews.com assumed coverage on shares of Sangamo Therapeutics in a report on Sunday, July 28th. They set a “sell” rating for the company.

Sangamo Therapeutics Trading Down 10.7 %

Shares of NASDAQ SGMO traded down $0.26 during mid-day trading on Thursday, reaching $2.18. 5,717,917 shares of the company’s stock were exchanged, compared to its average volume of 6,921,396. The business has a fifty day simple moving average of $1.27 and a 200 day simple moving average of $0.84. Sangamo Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.18. The firm has a market capitalization of $453.92 million, a price-to-earnings ratio of -2.88 and a beta of 1.10.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. State Board of Administration of Florida Retirement System raised its stake in Sangamo Therapeutics by 61.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 23,650 shares during the period. Cubist Systematic Strategies LLC bought a new position in Sangamo Therapeutics during the second quarter worth $67,000. Meritage Portfolio Management increased its holdings in shares of Sangamo Therapeutics by 8.6% in the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 6,740 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Sangamo Therapeutics in the second quarter valued at about $89,000. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 38,850 shares during the period. Institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.